|
Our mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human diseases.
NexBio is recipient of the 4th Annual “Scientific American 50” Award for a medical treatment. Prior award winners include Genentech, IDEC Pharmaceuticals, and Vertex Pharmaceuticals. (click the icon on right for the press release)
NexBio is proudly listed as one of the Life Science Partners - a collaboration between the San Diego Natural History Museum and the BIOCOM Institute - in Celebration of Darwin’s 200th Birthday. (click Darwin's image on right to see Nexbio's name association with this celebration)
|
|
Fludase® is in clinical development as a first-in-class broad-spectrum prophylactic and therapeutic agent for Influenza-Like Illness caused by all annual and pandemic variations of influenza virus (IFV), including Pandemic Influenza A(H1N1) and avian H5N1, as well as parainfluenza. Fludase® is currently undergoing a Phase II clinical trial for the treatment of community acquired influenza.
|
|